Implantable cardioverter defibrillator treatment : benefits and pitfalls in the currently indicated population
Borleffs, C.J.W.
Citation
Borleffs, C. J. W. (2010, September 30). Implantable cardioverter defibrillator treatment : benefits and pitfalls in the currently indicated population. Retrieved from https://hdl.handle.net/1887/16004
Version: Corrected Publisher’s Version License:
Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/16004
Note: To cite this publication please use the final published version (if
applicable).
Implantable Cardioverter Defibrillator Treatment:
Benefits and Pitfalls in the Currently Indicated Population
Carel Jan Willem Borleffs
The studies described in this thesis were performed at the Department of Cardiology of the Leiden University Medical Center, Leiden, the Netherlands.
Cover: Daniël Samama
Lay-out and print: Optima Grafische Communicatie, Rotterdam, the Netherlands ISBN: 978-90-8559-063-7
Copyright © C. Jan Willem Borleffs, Leiden, the Netherlands. All right reserved, No part of this book may be reproduced or transmitted, in any form or by any means, without prior permission of the author.
Financial support to the costs associated with publication of this thesis from Astellas Pharma, AstraZeneca BV, Biotronik Nederland BV, Boehringer Ingelheim BV, Boston Sci- entific BV, GE Healthcare, J.E. Jurriaanse Stichting, MEDA Pharma BV, Merck Sharp &
Dohme BV, Novartis Pharma BV, Sanofi-Aventis BV, Schering-Plough BV, Servier Nederland BV, Siemens Nederland NV, St. Jude Medical Nederland BV, Toshiba Medical Systems Nederland, is greatly acknowledged.
Implantable Cardioverter Defibrillator Treatment:
Benefits and Pitfalls in the Currently Indicated Population
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden, op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties te verdedigen op donderdag 30 september 2010
klokke 16.15 uur
door
Carel Jan Willem Borleffs geboren te Pijnacker in 1981
Promotiecommissie
Promotores: Prof. dr. M.J. Schalij Prof. dr. J.J. Bax
Co-promotor: Dr. L. van Erven
Overige leden: Dr. M. Bootsma
Prof. dr. R.N.W. Hauer (UMC Utrecht)
Dr. A. Mosterd (Meander Medisch Centrum Amersfoort) Prof. dr. F.R. Rosendaal
Prof. dr. E.E. van der Wall
Ik ben misschien wat minder kind Dan destijds aan de start Maar alle dingen die ik doe Die doe ik met mijn hart.
Toon Hermans
Aan mijn ouders en aan Kim
Table of contents
Chapter 1 General introduction and outline of the thesis
Part I: Long-term follow-up and baseline risk stratification of ICD patients Chapter 2 Structured Care for Patients after Acute Myocardial Infarction: Sudden
Cardiac Death Prevention. Data from the Leiden MISSION! AMI study.
Europace 2010; 12: 378-384
Chapter 3 Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention ICD Recipients: Long-term Follow-up of the Leiden Out-of- Hospital Cardiac Arrest Study (LOHCAT).
Eur Heart J 2009; 30: 1621-1626
Chapter 4 Prognostic Importance of Atrial Fibrillation in Implantable Cardioverter Defibrillator Patients.
J Am Coll Cardiol 2010; 55: 879-885
Chapter 5 Clinical Importance of New-onset Atrial Fibrillation after Cardiac Resynchronization Therapy.
Heart Rhythm 2009; 6: 305-310
Chapter 6 Mortality Risk Score in Primary Prevention Implantable Cardioverter Defibrillator Recipients with Non-ischaemic or Ischaemic Heart Disease.
Eur Heart J 2010; 31: 712-718
Chapter 7 Prediction of Non-Benefit from Implantable Cardioverter Defibrillator Treatment in Primary Prevention Patients with Ischemic Heart Disease.
Submitted
Part II: New parameters in risk stratification
Chapter 8 Infarct Tissue Heterogeneity Assessed with Contrast-Enhanced Magnetic Resonance Imaging Predicts Spontaneous Ventricular Arrhythmia in Patients with Ischemic Cardiomyopathy and Implantable Cardioverter-Defibrillator.
Circ Cardiovasc Imaging 2009; 2:183-190
Chapter 9 Cardiac Sympathetic Denervation Assessed with 123-Iodine
Metaiodobenzylguanidine Imaging Predicts Ventricular Arrhythmias in Implantable Cardioverter-Defibrillator Patients.
J Am Coll Cardiol 2010;55:2769-2777
Chapter 10 Predicting Ventricular Arrhythmias in Patients with Ischemic Heart Disease: Clinical Application of the ECG derived QRS-T Angle.
Circ Arrhythm Electrophysiol 2009; 2: 548-554
Chapter 11 Right Ventricular Stimulation Threshold at ICD implant Predicts Device Therapy in Primary Prevention Patients with Ischemic Heart Disease
Europace 2010; in press
Part III: Mechanical aspects and complications of device therapy Chapter 12 Inappropriate Implantable Cardioverter Defibrillator Shocks:
Incidence, Predictors and Impact on Mortality.
J Am Coll Cardiol 2010; in press
Chapter 13 Requirement for Coronary Sinus Lead Interventions and Effectiveness of Endovascular Replacement during Long-term Follow-up after Implantation of a Resynchronization Device.
Europace 2009; 11: 607-611.
Chapter 14 Risk of Failure of Transvenous Implantable Cardioverter-Defibrillator Leads.
Circ Arrhythm Electrophysiol 2009; 2: 411-416 Chapter 15 Implementation of Lead Safety Recommendations.
Pacing Clin Electrophysiol 2010; 33: 431-6
Chapter 16 Recurrent Implantable Cardioverter-Defibrillator Replacement Is Associated with an Increasing Risk of Pocket-Related Complications.
Pacing Clin Electrophysiol 2010; in press
Summary, Conslusions and Future Perspectives Samenvatting, Conclusies en Toekomstperspectief List of publications
Dankwoord Curriculum Vitae
